Synapse - A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC)

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC) Meeting Abstract

Authors:	Lee, E. K.; Xiong, N.; Tayob, N.; Krasner, C. N.; Buss, M. K.; Campos, S. M.; Wright, A. A.; Liu, J. F.; Shea, M.; Yeku, O. O.; Castro, C. M.; Porter, R. L.; Stover, E.; Bouberhan, S.; Moroney, J. W.; Cannistra, S. A.; Penson, R. T.; Fleming, G. F.; Matulonis, U. A.; Konstantinopoulos, P. A.
Abstract Title:	A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC)
Meeting Title:	2021 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	15 Suppl.
Meeting Dates:	2021 Jun 4-8
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-05-20
Language:	English
ACCESSION:	WOS:000708120306330
DOI:	10.1200/JCO.2021.39.15_suppl.10517
PROVIDER:	wos
Notes:	Meeting Abstract: TPS5609 -- Source: Wos